Ipamorelin was designed against this backdrop, with selectivity as an explicit objective
Quick Answer: GLP-1 receptor agonists do not directly cause vision problems, but may worsen diabetic retinopathy in patients with pre-existing eye disease who experience rapid blood glucose improvements
Most adverse events reported in clinical trials were mild to moderate and resolved without intervention, but its important for patients to understand what they might experience, especially when trying this treatment for the first time
King Law Is Investigating Ozempic Claims Related to Severe Side Effects Allegedly Caused by Ozempic Our Ozempic Legal Team at King Law Contact an Ozempic Lawyer Today Key Takeaways Heres some key information about the Ozempic lawsuits: There are more than 3,700 claims across two MDLs filed since the litigation began in 2024 (the MDLs also include lawsuits for those injured by Wegovy, Mounjaro, and other GLP-1 drugs) Key legal claims against Novo Nordisk include failure to warn, negligence, negligent marketing, and product liability (for a pharmaceutical drug) Defendants are Novo Nordisk and Eli Lilly (which makes other GLP-1 drugs) There are two MDLs for the Ozempic injury claims: Number of pending claims in MDL 3094 as of July 1, 2026: 3,848 Number of pending claims in MDL 3163 as of July 1, 2026: 146 People can file individual Ozempic lawsuits or join the active MDLs The Honorable Karen S
,aspect=ignore)
